Terminal Care and the Value of Life Near its End
29 Pages Posted: 1 Feb 2010
There are 2 versions of this paper
Terminal Care and the Value of Life Near its End
Terminal Care and the Value of Life Near its End
Date Written: January 8, 2010
Abstract
Medical care at the end of life, estimated to contribute up to a quarter of US health care spending, often encounters skepticism from payers and policy makers who question its high cost and often minimal health benefits. It seems generally agreed upon that medical resources are being wasted on excessive care for end-of-life treatments that often only prolong minimally an already frail life. However, though many observers have claimed that such spending is often irrational and wasteful, little explicit and systematic analysis exists on the incentives that determine end of life health care spending. There exists no positive theory that attempts to explain the high degree of end-of life spending and why differences across individuals, populations, or time occur in such spending. This paper attempts to provide the first rational and systematic analysis of the incentives behind end of life care. The main argument we make is that existing theoretical and empirical analysis of the value of life do not apply, and often under-values, the value of life near its end and terminal care. We argue that several factors drive up the value of life near its end including the low opportunity cost of medical spending near ones death, the value of hope including living into new innovations, and potential positive effect of on the value of life from being frail. We calibrate the ex-post value of hope associated with treatments for HIV patients to be as much as 4 times as high as standard per-capita estimates of treatment effects and as many as two and a half times as high as aggregate values across all cohorts.
Keywords: Health Economics, Terminal Care, Health Spending
JEL Classification: I10, I11, I12
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Accounting for Future Costs in Medical Cost-Effectiveness Analysis
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments
By Mark Duggan and William N. Evans
-
Insurance and Incentives for Medical Innovation
By Alan M. Garber, Charles I. Jones, ...
-
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
-
By Tomas Philipson and Anupam B. Jena
-
Advances in Cost-Effectiveness Analysis of Health Interventions
-
The Welfare Effects of Public Drug Insurance
By Darius N. Lakdawalla and Neeraj Sood
-
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
By Tomas Philipson and Anupam B. Jena